SCHEMBL6028026

SCHEMBL6028026

CC1CCCCC1C(=O)Nc1ccc(-c2ncc(-c3ccc(C(=O)NC4CCCCCC4)cc3)[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
CYP1A2 P05177 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NAMPT P43490 3/20 0.41
EPHX2 P34913 2/20 0.40
SCN3A Q9NY46 2/20 0.40
SCN9A Q15858 1/20 0.40
KIT P10721 1/20 0.40
RIPK1 Q13546 1/20 0.40
EPHX1 P07099 1/20 0.39
MAPKAPK2 P49137 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6027061 0.88 PTPN1 (0.50) KMT2AKDM4EMEN1RXFP1NPC1
SCHEMBL6028629 0.88 PTPN1 (0.50) KMT2AKDM4EMEN1RXFP1NPC1
SCHEMBL6885545 0.87 ABL1 (0.45) KMT2AKDM4EMEN1RXFP1NPC1
SCHEMBL6029811 0.86 PTPN1 (0.51) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL6031823 0.86 PTPN1 (0.51) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL6888068 0.86 PTPN1 (0.51) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL6030700 0.86 PTPN1 (0.51) KDM4ENPC1RAB9AHPGDSMN1; SMN2
SCHEMBL6026031 0.84 MEN1 (0.52) KMT2AKDM4EMEN1RXFP1NPC1
SCHEMBL6885880 0.83 SCN3A (0.42) KMT2AKDM4EMEN1NPC1RAB9A
SCHEMBL6887689 0.83 PTPN1 (0.44) KMT2AKDM4EMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613310-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS Avanir Pharmaceuticals (US) 2006-01-11 EP disclosed
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders AVANIR PHARMACEUTICALS 2004-11-18 US disclosed
WO-2004091610-A1 IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS AVANIR PHARMACEUTICALS (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229927-A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders ICOS, TSLP, IKZF3 KMT2A 361/4885KDM4E 543/4885MEN1 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.